Ann: Imagion and Patrys collaborate on new cancer imaging agents, page-18

Hi all,

Today we announced a partnership with Patrys Limited (ASX: PAB), a therapeutic antibody development company, for a collaborative research program using our combined technologies to improve brain tumor imaging and diagnosis.

The collaboration aims to pair the targeting specificity of Patrys’ novel deoxymabs with the imaging capabilities of the theMagSense® technology to provide a highly effective imaging agent with high specificity for hard-to-diagnose cancers such as brain cancer.

Our preliminary research has already demonstrated that the Patrys PAT-DX1 molecule can be conjugated to the MagSense® nanoparticles and provide bio-functionality for targeting certain cancer cell lines. Positive results from this collaborative research will give Imagion an exclusive option to a future license agreement, should we elect to commercialize the imaging agent. Under the current collaboration, both parties are bearing their own costs.

Read the full announcement here